Liver-Based mRNA Therapy Restores Immune Function in Aging Mice
Novel mRNA treatment targeting the liver successfully rejuvenated aged immune systems and improved vaccine responses in mice.
Summary
Researchers developed a novel approach to combat age-related immune decline by delivering mRNAs encoding three immune-supporting factors (DLL1, FLT3-L, and IL-7) to the liver using lipid nanoparticles. In aged mice, this treatment expanded immune cell precursors, boosted thymus function, enhanced vaccine responses, and improved anti-tumor immunity. The effects were reversible and didn't cause autoimmune reactions, unlike traditional cytokine therapies. This liver-based strategy offers a promising new direction for preserving immune function during aging.
Detailed Summary
Age-related immune decline represents one of the most significant challenges in longevity research, as the aging immune system becomes increasingly vulnerable to infections, cancers, and vaccine failures. The thymus, which produces T cells crucial for immune function, shrinks dramatically with age, leading to a weakened and less diverse immune repertoire.
Researchers at MIT and Harvard developed an innovative approach to address this problem by repurposing the liver as a temporary factory for immune-supporting factors. They first conducted comprehensive multi-omic mapping across young and aged mice to identify which immune signaling pathways decline with age. This analysis revealed that Notch signaling, FLT3-L, and IL-7 pathways were particularly diminished in older animals.
The team then engineered mRNAs encoding three key factors: Delta-like ligand 1 (DLL1) for Notch activation, FLT3-L for dendritic cell support, and IL-7 for T cell maintenance. These mRNAs were packaged in lipid nanoparticles and delivered systemically, with the liver serving as the primary target organ for protein production.
The results were remarkable. Treatment with these mRNAs (termed DFI) expanded common lymphoid progenitors, boosted new T cell production in the thymus without affecting stem cell populations, and replenished the T cell pool while enhancing dendritic cell function. Most importantly, aged mice showed dramatically improved responses to peptide vaccines and restored anti-tumor immunity, with increased tumor-infiltrating CD8+ T cells and enhanced clonal diversity.
Unlike traditional cytokine therapies that often cause severe side effects, this mRNA approach was well-tolerated and reversible. The effects disappeared after treatment ceased, and there was no evidence of autoimmune reactions or breach of self-tolerance. The treatment also synergized effectively with immune checkpoint blockade therapy.
This research represents a significant advance in immunogerontology, offering a potentially safer and more effective approach to immune rejuvenation than current methods. The liver-based delivery system could serve as a platform for addressing other age-related declines in circulating factors.
Key Findings
- mRNA delivery to liver restored three key immune factors declining with age
- Treatment expanded T cell precursors and boosted thymus function in aged mice
- Vaccine responses improved 3-fold and anti-tumor immunity was restored
- Effects were reversible with no autoimmune side effects unlike cytokine therapy
- Approach synergized with checkpoint inhibitors for enhanced cancer treatment
Methodology
Researchers used multi-omic profiling including single-cell RNA sequencing and spatial transcriptomics across the mouse lifespan to identify declining immune factors. mRNAs were delivered via SM-102 lipid nanoparticles with hepatocyte-targeted expression confirmed by RIBOmap imaging.
Study Limitations
Study was conducted only in mice with relatively short treatment periods. Long-term safety, optimal dosing regimens, and translation to human aging biology require further investigation. The approach targets specific pathways and may not address all aspects of immune aging.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.